Ignite Creation Date:
2024-05-06 @ 6:01 PM
Last Modification Date:
2024-10-26 @ 2:40 PM
Study NCT ID:
NCT05518617
Status:
RECRUITING
Last Update Posted:
2023-12-07
First Post:
2022-07-25
Brief Title:
Molecular and Functional Imaging in Monogenic PD
Sponsor:
University of Exeter
Organization:
University of Exeter
Study Overview
Official Title:
Molecular and Functional Imaging of Parkinsons Pathology in SNCA Parkin and PINK1 Mutation Carriers
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FOX_1
Brief Summary:
In this study the investigators aim to find a biomarker of Parkinsons disease This is done using imaging scans called Positron Emission tomography PET Single Photon Emission Computed Tomography SPECT and Magnetic Resonance Imaging MRI The findings will provide a deeper understanding of the brain changes in Parkinsons disease More importantly this study will help with the discovery and development of new medications aiming to delay progression of PD symptoms
Detailed Description:
The purpose of this study is to find a biomarker for Parkinsons disease PD A biomarker is an indicator of the presence of a disease that can be measured and that is able to give information about the progression or severity of it
PD is a chronic neurological disease that progresses over time and causes a variety of symptoms such as slowness of movement stiffness and shaking The symptoms of PD are caused by the malfunction and death of vital nerve cells in the brain it is no known what causes PD and there is no biomarker for it
Generally PD occurs without a known cause and is called sporadic PD In a few cases however PD occurs because of a genetic mutation and it is called genetic PD Patients with genetic PD share features to sporadic PD patients It is believed that studying people who carry mutations for genetic PD mutations would provide precious information on what are the causes of PD and help to devise successful treatments
Participants will attend 4 visits in a 3 month period These visits include an initial consent and assessment visit where some blood samples will also be taken the second visit involves a PET scan with the tracer DASB along with an MRI scan The third visit involves a SPECT scan the fourth visit is optional and would be for a lumbar puncture visit Each visit will last around 6 hours
PD is a chronic neurological disease that progresses over time and causes a variety of symptoms such as slowness of movement stiffness and shaking The symptoms of PD are caused by the malfunction and death of vital nerve cells in the brain it is no known what causes PD and there is no biomarker for it
Generally PD occurs without a known cause and is called sporadic PD In a few cases however PD occurs because of a genetic mutation and it is called genetic PD Patients with genetic PD share features to sporadic PD patients It is believed that studying people who carry mutations for genetic PD mutations would provide precious information on what are the causes of PD and help to devise successful treatments
Participants will attend 4 visits in a 3 month period These visits include an initial consent and assessment visit where some blood samples will also be taken the second visit involves a PET scan with the tracer DASB along with an MRI scan The third visit involves a SPECT scan the fourth visit is optional and would be for a lumbar puncture visit Each visit will last around 6 hours
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None